In this interview, we spoke with Viviane Labrie about her research into the vermiform appendix as a possible contributor to Parkinson’s disease.
Whilst at the ARUK Conference 2019, we had the pleasure of speaking with Hugh Perry about neuroinflammation and Alzheimer’s disease, particularly the role of microglia in brain homeostasis.
We had the pleasure of filming a joint seminar from the Michael J Fox Foundation and Abcam on biomarkers of neuroinflammation in Parkinson’s disease. Discover more about this in our video, with timepoints for each slide included.
A new imaging study will be the first to use the GE180 ligand tracer to detect neuroinflammation in Parkinson’s and Alzheimer’s disease brains.
Sarah Isabel Sheikh talks to Neurodegenerative Disease Management about her research into the development of neuroregenerative-based therapies for multiple sclerosis.
In this edition of NCTalks, we speak to Robyn Klein as part of our Spotlight on neuroimmunology – Robyn discusses her research, how inflammatory processes contribute to neurologic disease, and whether immunology and inflammation could be the basis of an eventual preventative treatment for neurodegenerative disease.
This Spotlight will explore every corner of neuroimmunology, looking in-depth at the history of the field, new uses for the immune system in a wealth of neurological diseases, and looking ahead at the future of this ever-expanding field.
A retrospective review of medical records reveals that the presence of a novel autoantibody in a patient’s serum is indicative of autoimmune meningoencephalomyelitis.
In this editorial, the authors focus on TBIs that result in brain hemorrhage. On the battlefield, it is likely to be overlooked in favor of more readily visible injuries, yet bleeding and inflammation within the head can cause death or pervasive ongoing psychiatric conditions.
Elucidating the link between the modifiable risk factors of Alzheimer’s disease and neuroinflammation
In this Special Report, the authors highlight the link between select modifiable risk factors and neuroimmune mechanisms, and demonstrate that by controlling microglial activation and neuroinflammation the prevalence of AD may be decreased.